This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Saunders RN, Metcalfe MS, Nicholson ML . Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59: 3–16.
Augustine JJ, Bodziak KA, Hricik DE . Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369–391.
Cutler C, Antin JH . Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 471–476.
Mahé E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476–482.
Özcan D, Seçkin D, Ada S, Haberal M . Mucocutaneous disorders in renal transplant recipients receiving sirolimus-based immunosuppressive therapy: a prospective, case-control study. Clin Transplant 2013; 27: 742–748.
Fricain JC, Cellerié K, Sibaud V, Catros S, Taïeb A, Merville P . Oral ulcers in kidney allograft recipients treated with sirolimus. Ann Dermatol Venereol 2008; 135: 737–741.
Neff GW, Montalbano M, Slapak-Green G, Meyer D, Berney T, Safdar K et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003; 35: 3029–3031.
Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264–268.
Schaffellner S, Jakoby E, Kniepeiss D, Stadlbauer V, Duller D, Iberer F et al. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus. Int Immunopharmacol 2005; 5: 137–140.
Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 47–55.
Busca A, Locatelli F, Moscato D, Falda M . Sirolimus-related toxicity in stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 647–649.
Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–1929.
Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124: 1372–1377.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Haïk, L., Beylot-Barry, M., Vigouroux, S. et al. Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation. Bone Marrow Transplant 51, 132–133 (2016). https://doi.org/10.1038/bmt.2015.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.198
This article is cited by
-
Sirolimus
Reactions Weekly (2016)